Inside Nasal Peptide Formulations: Ingredients, Containers and Storage Evidence

A solution changes the peptide’s surroundings

In a nasal formulation, water is more than a carrier. Dissolved peptide molecules encounter the liquid’s pH, other ingredients and the container surface. Depending on the molecule and conditions, chemical degradation, aggregation or adsorption to packaging can affect the preparation. A liquid can remain clear while its composition changes.

Buffers help control pH; other ingredients can adjust physical properties or limit microbial growth. These functions are not interchangeable. Preserving against microbial growth does not necessarily preserve the peptide’s chemical structure.

What the disclosed preservative tells us

Crystal describes its nasal formulation as proprietary, with confidential ingredient proportions, and identifies m-cresol, also called metacresol, among its ingredients. This is manufacturer-supplied information, not independent confirmation of the formulation’s composition or performance.

M-cresol serves as an antimicrobial preservative in some multidose pharmaceutical formulations. Its presence does not establish sterility, nasal suitability or a storage period. Heljo et al. examined peptide–preservative interactions, illustrating why preservatives must also be considered as participants in the molecular environment. That research does not validate Crystal’s formulation or make m-cresol a universal stabiliser.

The bottle belongs in the evidence

A storage claim concerns a formulation inside a particular container, not just a molecule in water. Contact with bottle and pump materials, closure performance and repeated actuation can matter. Evidence from an unopened container does not automatically describe a bottle in use.

The EMA guideline on inhalation and nasal product quality provides regulatory context for assessing formulation and delivery performance together. It is not evidence that a particular research spray meets those expectations.

Why “60 days” needs its accompanying conditions

The 2025 kisspeptin-54 nasal study by Mills and colleagues included an evaluation of the researchers’ solution in specified containers at 4°C for 60 days. The useful finding is bounded by that preparation, container, temperature and observation period.

It does not establish 60 days at room temperature, nor a shelf life for another peptide. Even a study involving nasal administration cannot make its formulation findings transferable to every nasal product.

Reading a storage claim without seeing the recipe

A useful evidence summary identifies the tested preparation, container, temperature range, duration and acceptance criteria. It also distinguishes unopened storage from in-use assessment. The ICH Q1A(R2) stability guideline supplies a framework for such evidence—not a product-specific expiry date.

Content assay, degradation testing, microbial assessment and pump performance answer separate questions. Chromatographic area percentage alone establishes neither retained peptide quantity nor microbial quality or consistent delivery.

Confidential proportions need not prevent clear reporting of these results. Without them, no new room-temperature period should be inferred. For the separate question of what happens after spraying, see how nasal peptide delivery works.